Glaukos has claimed a series of regulatory clearances in Europe for its micro-scale surgical implants to treat patients with ...

The iStent infinite Trabecular Micro-Bypass System Model iS3 is for minimising IOP in those with primary open-angle glaucoma.

The glaucoma treatment market is expected to witness steady growth between 2025 and 2035, driven by the increasing prevalence of glaucoma, advancements in treatment options, and rising awareness about ...